
Neuroventis
Operates as a digital platform for neurology.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
* | N/A | - | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Neuroventis, now part of Cascador Health, operates as a digital health company focused on the neurology sector. The company was founded in 2017 with its headquarters in Overijse, Belgium. Its origin is tied to the personal experience of co-founder Sanawar Syed, whose family member lives with epilepsy, sparking the mission to use software and data to support patients and physicians. The founding team also includes business experts Jonathan Schreiber and Ludovic Ampe, and neurologist Peter Dedeken. A key milestone for the company was winning a hackathon organized by UCB in 2016-2017, which provided an early breakthrough. By March 2021, Neuroventis had secured €1 million in funding to support its international expansion. In late 2024, the company merged with Cascador Health, a leader in Real-World Data, to enhance its capabilities in large-scale medical data utilization for research.
Neuroventis' business model centers on creating a digital bridge between patients with neurological conditions and their healthcare providers. The company targets both patients and medical teams, including neurologists, hospitals, and clinical researchers. Revenue is generated by providing its platform to pharmaceutical companies for clinical studies and by working with healthcare providers to integrate the system into their workflows, while the patient-facing applications are free to use. The company's digital platform is a CE-marked, FDA-registered, ISO 13485 & ISO 27001 certified medical device software.
The core of Neuroventis' offering is a comprehensive digital platform that includes two primary patient-facing applications: Helpilepsy for epilepsy and MigraineManager for headache disorders. These mobile apps function as personal assistants, allowing users to log seizures or headache attacks, track symptoms, monitor medication adherence and side effects, and set reminders. The applications are designed to empower patients by helping them understand their condition and prepare for consultations through personalized reports. For healthcare professionals, the Neuroventis dashboard provides a consolidated, real-time view of patient-reported data. This dashboard visualizes patient history and trends, enabling more objective, data-driven treatment decisions and allowing more time for patient interaction during appointments. The platform also supports integration with medical hardware, like the NightWatch seizure detection device, and can connect with electronic patient records to streamline data flow.
Keywords: digital neurology, epilepsy monitoring, migraine tracking, remote patient monitoring, digital health platform, real-world evidence, clinical trial data, Helpilepsy, MigraineManager, patient empowerment, neurology software, digital therapeutics, healthcare data analytics, CE-marked medical device, Cascador Health, patient-reported outcomes, digital diary, medication adherence, seizure detection, headache management